The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
| Factor | Score | Distribution | Value | Avg | Verdict |
|---|---|---|---|---|---|
Valuation | 28 | 54.0x | 20.1x | Below average | |
Growth | 92 | 56.7% | 5.6% | Above average | |
Quality | 77 | 19.6% | 7.6% | Above average | |
Safety | 89 | -1.7x | 0.4x | Above average | |
Capital Return | 41 | — | 2.19% | Near average | |
Momentum | — | — | — | No data | |
Sentiment | — | — | — | No data |
Kiniksa Pharmaceuticals, Ltd. is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.
You can buy Kiniksa Pharmaceuticals, Ltd. shares through a licensed brokerage. Research the company's financials before investing.
Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.
Dividend policies vary by company. Check the dividends section on the stock page for the payout history.
Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.
AI analysis from the earnings call, financials and news
This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.
KNSA stock shows remarkable stability in analyst estimates over the past 30 days, with the average target price steadying at 64 dollars based on a consensus of 6 analysts. This consistency reflects a state of temporary valuation certainty, with a positive price gap (Upside) compared to the current price of 53.24 dollars, as the price range fluctuates between 59 and 71 dollars, indicating Low Dispersion and unified confidence in the stock's fair value.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.